AMORF LETERMOVIR OG FASTE FARMACEUTISKE FORMULERINGER DERAF TIL ORAL INDGIVELSE

The immediate release formulations of amorphous Letermovir are intended for use in methods of prophylaxis or methods of treatment of diseases associated with the group of Herpesviridae, preferably associated with cytomegalovirus (CMV), even more preferably associated with human cytomegalovirus (HCMV...

Full description

Saved in:
Bibliographic Details
Main Authors LIMMERT, Michael, BERWE, Mathias, SCHWAB, Wilfried, SCHICKANEDER, Christian, RINDERMANN, Nicole, MÄRTENS, Welljanne, BOTHE, Clemens, JUNG, Dirk
Format Patent
LanguageDanish
Published 24.06.2019
Subjects
CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:The immediate release formulations of amorphous Letermovir are intended for use in methods of prophylaxis or methods of treatment of diseases associated with the group of Herpesviridae, preferably associated with cytomegalovirus (CMV), even more preferably associated with human cytomegalovirus (HCMV).
Bibliography:Application Number: DK20140732545T